标题：孟鲁司特钠对稳定期慢性阻塞性肺疾病患者血液流变学指标及肺功能的影响

      作者：苏方华，周志勤，冉贤金
    (中国中信集团惠州医院，广东 惠州 516006)

      卷次： 2014年25卷17期

      【摘要】 目的 探讨孟鲁司特钠对稳定期慢性阻塞性肺疾病(COPD)患者血液流变学指标及肺功能的影
响。方法 50例稳定期COPD患者随机分为两组各25例，对照组予常规治疗，观察组在此基础上联用孟鲁司特
钠，观察两组患者治疗前后血液流变学指标及肺功能的变化。结果 治疗前两组患者全血黏度(包括高切、中切、
低切)、血浆黏度、红细胞压积、纤维蛋白原比较差异无统计学意义(P>0.05)，治疗后观察组上述指标水平较治疗
前明显降低，差异有统计学意义(P<0.05)；对照组上述指标水平治疗前后比较差异无统计学意义(P>0.05)，且治疗
后观察组上述指标明显低于对照组，差异有统计学意义(P<0.05)；治疗前两组患者肺功能 FEV1/预计值、FEV1/
FVC比较差异无统计学意义(P>0.05)；观察组治疗后上述肺功能指标水平均较治疗前显著提高，差异有统计学意
义(P<0.05)；对照组上述指标治疗前后比较差异无统计学意义(P>0.05)；且治疗后观察组上述指标明显低于对照
组，差异有统计学意义(P<0.05)。结论 孟鲁斯特钠不仅可以抑制COPD患者的炎症反应，并且能够通过改善患
者的血液流变性从而改善患者肺功能，提高患者的生活质量。

      【关键词】 慢性阻塞性肺疾病；血液流变学；肺功能；孟鲁司特钠

      【中图分类号】 R563 【文献标识码】 A 【文章编号】 1003—6350（2014）17—2517—03


Effect of montelukast on hemorheology and lung function in patients with stable chronic obstructive
pulmonary disease.
SU Fang-hua, ZHOU Zhi-qin, RAN Xian-jin. Department of Internal Medicine, CITIC Huizhou
Hospital, Huizhou 516006, Guangdong, CHINA

【Abstract】 Objective To determine the therapeutic effect of hemorheology and lung function with montelu-
kast on patients with stable chronic obstructive pulmonary disease (COPD). Methods Fifty patients with stable
COPD were randomly divided into two groups: the control group received conventional treatment, and the observation
group combined with montelukast. The hemorheology and lung function changes were compared. Results Before
treatment, the whole blood viscosity (including high-cut, medium and low shear), plasma viscosity, hematocrit, fibrino-
gen in the two groups showed no significant difference (P>0.05). The obove indexes was lower than before treatment
and control group in observation group, and the difference was statistically significant (P<0.05). There were no signifi-
cant changes in these indicators in control group (P>0.05); Before treatment, there were no significant difference in
the function of FEV1/predicted, FEV1/FVC in the two groups (P>0.05), but that in observation group was increased
than before treatment and control group, with statistically significant difference (P<0.05); there were no significant
change in control group (P>0.05). Conclusion Montelukast can inhibit the inflammatory response in COPD patients,
and can improve the patient's blood rheology to improve the lung function and quality of life.